<p>
    HCV-Positive Recipients
</p>
<ul>
    <li data-list-item-id="ebf4ab9676fdb637dcde531bba33c48cb">
        <strong>Immunosuppression</strong>: Use higher Tacrolimus; avoid solumedrol boluses. Do not use depleting induction therapy.
    </li>
    <li data-list-item-id="eb8f0d296aad24df7563e1cfb6b7a6529">
        <strong>Monitoring</strong>: Check HCV-RNA at week 2 post-transplant.
    </li>
    <li data-list-item-id="e1bcadcc25696a96c4c23186c9c4c61f6">
        <p>
            <strong>Antiviral Therapy: </strong>If RNA positive, start antiviral therapy (e.g., Epclusa or Maviret) beyond 3 months post-transplant.
        </p>
        <ul>
            <li data-list-item-id="ee902d0d4f82c1491f0505d2ed8131095">
                May consider earlier treatment if active hepatitis; liver biopsy recommended to rule out TCMR
            </li>
        </ul>
        <p>
            &nbsp;
        </p>
    </li>
</ul>
<p>
    HBV-Positive Recipients
</p>
<ul>
    <li data-list-item-id="e4fe02487126ce534c2580c17dbff5ce8">
        &nbsp;&nbsp;<strong> If HBV-DNA negative at transplant</strong>: Life-long nucleos(t)ide analogs (NUCs). Step up LAM to tenofovir if necessary.
    </li>
    <li data-list-item-id="e56e03d32d6bdb2cf8d7db89c86b02cad">
        &nbsp;&nbsp;<strong> If HBV-DNA positive at transplant</strong>: Use HBIG protocol + NUCs:
        <ul>
            <li data-list-item-id="e8d9b24ef81e4fd2a9bcee9a2f4810ea0">
                HBIG 10 mL IV during anhepatic phase, then:
                <ul>
                    <li data-list-item-id="e5ce8101270bb5f1ce6ac794f1d09fdd5">
                        Daily x1 week, weekly x4 weeks, monthly x12 months.
                    </li>
                    <li data-list-item-id="ed2c7106ab34699d5bd6971cebd147ed7">
                        Maintain anti-HBs &gt;100 IU/mL.
                    </li>
                </ul>
            </li>
        </ul>
    </li>
    <li data-list-item-id="edea24c85da4e6f6dbf7247f7fc01a94f">
        &nbsp;&nbsp;<strong> If high HBV viral load (&gt;4 logs):</strong>
        <ul>
            <li data-list-item-id="e98469bf769441743cc6a56e1fee30550">
                Use <strong>High-Dose HBIG Protocol:</strong>
                <ul>
                    <li data-list-item-id="ed30d92c7b85e6b3801da8b0bda82bea2">
                        10,000 IU IV at anhepatic phase.
                    </li>
                    <li data-list-item-id="e284a43159f4ac9dca8425267f8f60904">
                        1500 IU/day Days 1–7, weekly x1 month, then monthly 1000–2000 IU.
                    </li>
                    <li data-list-item-id="ec963852b2964fdf5d55143b9efd940de">
                        <p>
                            Monitor anti-HBs titers (&gt;100 IU/mL)
                        </p>
                        <p>
                            &nbsp;
                        </p>
                    </li>
                </ul>
            </li>
        </ul>
    </li>
</ul>
<p>
    HBV/HDV Co-Infected Recipients
</p>
<ul>
    <li data-list-item-id="e85ee00fef6f12b0b3fd06686e7685a2e">
        <strong>Therapy</strong>: Life-long HBIG + NUCs. Reinfection always leads to cirrhosis.
    </li>
    <li data-list-item-id="ec24e475ff025da66a42613122355e2a8">
        <p>
            <strong>Goal</strong>: Maintain anti-HBs &gt;50 IU/mL.
        </p>
        <p>
            &nbsp;
        </p>
    </li>
</ul>
<p>
    HEV-Positive Recipients
</p>
<ul>
    <li class="ck-list-marker-bold" data-list-item-id="e2fc30da04f94e787a0e6487eb3233cc3">
        <strong>&nbsp; &nbsp;Acute Liver Failure Triggered by HEV:</strong>
        <ul>
            <li data-list-item-id="e237666408b41392b8f4bc12d158043dd">
                Avoid induction with basiliximab.
            </li>
            <li data-list-item-id="e1b965a719a632afc70704eb2d3a5eb7d">
                Consider IVIG during anhepatic phase (1.5 mg/kg).
            </li>
            <li data-list-item-id="eb80559b3bfa4a25008fd7e28f5e26290">
                If PCR-positive post-transplant with hepatitis, consider <strong>ribavirin</strong>, but note early infection risk.&nbsp;
            </li>
        </ul>
    </li>
</ul>